2.8000.00% ( 0.000 )
Suspended: Oct 23, 09:20:00 (EDT)Current ValuationThe current P/E ratio is -0.16, within the reasonable range, cheaper than 46.66% of the time in the past 5 years, and the industry ranks 6/14, the industry Median -0.06.
-0.162xP/E
--Stock price
-0.162xP/E
Stock price--
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.32x
- Typical range
- -25.87x–13.45x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
09182736
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x10x20x30x40x50x
| Name/Symbol | |||
|---|---|---|---|
AHCOUSAdaptHealth | -3.61x | 145.62% | $820.79M |
AHGUSAkso Health | -38.42x | -- | $717.42M |
COSMUSCosmos Health | -1.08x | 65.08% | $26.27M |
ACHUSAccendra Health | -0.06x | 89.52% | $16.71M |
ZSTKUSZeroStack | -0.04x | 90.76% | $7.97M |
MEDSUSDataMeds AI | -0.08x | -- | $6.83M |
POMUSPomdoctor | -0.06x | -- | $3.25M |
ATPCUSAgape ATP | -1.23x | -- | $1.40M |
VRAXUSVirax Biolabs | -0.19x | 52.53% | $972.26K |
BIMIUSBIMI International Medical | -- | -- | $5.58K |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
